Growth Metrics

AbCellera Biologics (ABCL) Receivables (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Receivables for 6 consecutive years, with $41.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 32.14% year-over-year to $41.5 million, compared with a TTM value of $41.5 million through Sep 2025, up 32.14%, and an annual FY2024 reading of $32.0 million, changed N/A over the prior year.
  • Receivables was $41.5 million for Q3 2025 at AbCellera Biologics, down from $70.0 million in the prior quarter.
  • Across five years, Receivables topped out at $334.4 million in Q1 2022 and bottomed at $20.0 million in Q1 2023.
  • Average Receivables over 5 years is $79.4 million, with a median of $44.7 million recorded in 2021.
  • The sharpest move saw Receivables skyrocketed 142.85% in 2022, then crashed 94.02% in 2023.
  • Year by year, Receivables stood at $160.6 million in 2021, then plummeted by 75.97% to $38.6 million in 2022, then decreased by 2.97% to $37.4 million in 2023, then decreased by 14.6% to $32.0 million in 2024, then increased by 29.63% to $41.5 million in 2025.
  • Business Quant data shows Receivables for ABCL at $41.5 million in Q3 2025, $70.0 million in Q2 2025, and $63.6 million in Q1 2025.